IDDF2020-ABS-0178 Switching off immunosuppressive myeloid cells by targeting cell cycle-related kinase pathway: a new strategy for combination immunotherapy
Hepatocellular carcinoma (HCC) is characterized by a robustly immunosuppressive tumor microenvironment (TME) that often renders immune-checkpoint-blockade (ICB) therapies ineffective. A central component of this TME is the myeloid-derived suppressor cell (MDSC), which actively inhibits T cell function. While previous research identified the role of cell-cycle-related kinase (CCRK, or CDK20) within tumor cells, this study investigates whether CCRK also governs the identity and suppressive capacity of the immune cells themselves.
Methodology
To explore the role of CCRK in the immune landscape, researchers utilized a combination of human patient samples and murine models. The study involved:
Expression Analysis: Flow cytometry was used to profile CCRK expression in immune cells sorted from HCC patients and tumor-bearing mice.
Functional Assays: CCRK was silenced in human blood-derived MDSCs to observe changes in cell differentiation and function.
Mechanistic Mapping: The team employed qChIP-PCR and multi-color flow cytometry to trace signaling pathways, specifically focusing on the STAT3 and E4BP4 axes.
In Vivo Validation: Modified MDSCs were injected into orthotopic HCC mouse models to evaluate their impact on tumor growth and T cell activation.
Key Insights and Results
The study identified CCRK as a critical molecular switch in myeloid cell behavior:
Cell-Specific Overexpression: CCRK is specifically upregulated in MDSCs but not in lymphocytes, providing a precise therapeutic target within the TME.
Phenotypic Reprogramming: Blockade of CCRK in MDSCs induces their differentiation into antigen-presenting macrophages. Instead of suppressing the immune system, these reprogrammed cells actively promote T cell priming.
Signaling Cascade Correction: CCRK inhibition suppresses STAT3 signaling, which in turn corrects an E4BP4-dependent imbalance between the suppressive cytokine IL-10 and the stimulatory cytokine IL-12. It also reduces the expression of arginase I, an enzyme used by MDSCs to inhibit T cell activity.
Anti-Tumor Efficacy: In mouse models, targeting the myeloid-intrinsic CCRK signal significantly amplified anti-tumor T cell responses and reduced overall tumorigenicity.
Conclusion and Future Directions
These findings demonstrate that targeting the CCRK pathway in myeloid cells can effectively "switch off" immunosuppression and "switch on" anti-tumor immunity. This approach offers a promising strategy for combination immunotherapy, potentially improving response rates for patients with solid tumors like HCC. Future research will focus on developing selective small-molecule CCRK inhibitors and testing their efficacy in combination with existing ICB therapies in clinical settings.
Summary updated
Abstract
<h3>Background</h3> The immune-checkpoint-blockade (ICB) therapy has produced promising and yet modest objective response rates in hepatocellular carcinoma (HCC), which has been attributable to the strong immunosuppressive tumor microenvironment (TME). As a key player in the TME, myeloid-derived suppressor cell (MDSC) shows potent T cell-suppressive activity that remarkably associates with poor prognosis and ICB resistance of cancer patients. While targeting MDSC can blunt T cell activity, a new approach is directed towards driving MDSC differentiation into antigen presentation cell crucial for T cell priming and activation. We have recently shown that hepatoma-intrinsic cyclin-dependent-kinase 20 (CDK20), or cell-cycle-related-kinase (CCRK) depletion diminishes MDSC-mediated immunosuppression leading to improved ICB efficacy (<i>Gut</i> 2018). As emerging evidence highlights the key roles of immune cell-intrinsic CDKs, we aimed to further explore the potentials of CCRK in immune cell identity. <h3>Methods</h3> The expression profile of CCRK was determined in flow-sorted immune cells from tumor-bearing mice and HCC patients. Functional significance and molecular mechanisms of CCRK in MDSCs were conducted by gene knockdown in human blood-derived MDSCs, followed by mRNA and protein detection, qChIP-PCR and multi-colour flow cytometry. The MDSC differentiation and T cell suppression in tumorigenicity were validated in HCC mouse model with intratumoral MDSC injection. <h3>Results</h3> We uncovered specific over-expression of CCRK in MDSCs but not lymphocytes from tumor-bearing mice and HCC patients. Notably, blockade of MDSC-intrinsic CCRK induced its differentiation into antigen-presenting macrophage, which amplified T cell responses in vitro and in vivo, resulting in reduced tumorigenicity. CCRK inhibition suppressed signal transducer and activator of transcription 3 (STAT3) signaling to revert E4-binding protein 4 (E4BP4)-dependent interleukin-10 (IL-10)/IL-12 imbalance and arginase I expression, thus blunting immunosuppression. <h3>Conclusions</h3> Our findings demonstrate that targeting myeloid-intrinsic CCRK signal can amplify anti-tumor T cell responses. As we also showed CCRK overexpression in patient-derived MDSCs, our results not only unravel mechanistic insights in MDSC identity but also offer a novel therapeutic kinase-target for a combinational immunotherapy strategy for conferring durable eradication of solid tumors.
BibTeX
@inproceedings{zhou2020iddf,
author = {Jingying Zhou and Joseph J.�Y. Sung and Alfred S.L. Cheng},
title = {{IDDF2020-ABS-0178 Switching off immunosuppressive myeloid cells by targeting cell cycle-related kinase pathway: a new strategy for combination immunotherapy}},
booktitle = {Abstracts},
year = {2020},
doi = {10.1136/gutjnl-2020-iddf.36},
}